STOCK TITAN

Becton, Dickinson and Co. - BDX STOCK NEWS

Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.

Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.

BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.

Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.

In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.

BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.

Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.

With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.

Rhea-AI Summary

BD (NYSE: BDX) has entered into a collaboration with Biocorp to enhance self-administered drug therapies through connected technology. The partnership aims to integrate Biocorp's Injay® technology with BD's UltraSafe Plus™ Passive Needle Guard, allowing biopharmaceutical manufacturers to capture and transmit injection data. This innovation is expected to improve patient adherence to injectable drugs. The connected drug delivery market is projected to grow significantly as digital technologies and self-administered therapies become more prevalent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) will announce its fiscal 2022 fourth quarter and full year financial results on November 10, 2022, at approximately 6:30 a.m. ET. The announcement will provide summarized financial information for the quarter and full year ending on September 30, 2022.

An audio webcast will follow at 8 a.m. ET on the same day to discuss the results and company operations. Investors can access the release and the webcast on BD's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) has announced a grant of $360,000 to six U.S. free clinics as part of its Point-of-Care, Enhancing Clinical Effectiveness initiative. This program, established in 2017, has supported 27 clinics across 20 states with a total of $2.6 million. The initiative aims to improve health outcomes in underserved communities by providing diagnostic testing capabilities for common health issues, impacting over 16,500 patient visits this year. Collaborating partners include Heart to Heart International and the National Association of Free and Charitable Clinics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has launched the BD® Research Cloud, a cloud-based software designed to enhance flow cytometry workflows. This integrated ecosystem aids scientists in optimizing panel design, collaboration, and data analysis across various research fields like immunology and oncology. Developed by the creators of FlowJo™ Software, it streamlines the workflow by connecting instruments to data analysis, enabling more efficient experiments and faster insights. The platform is built on a reliable cloud infrastructure and aims to support future advancements in flow cytometry research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
-
Rhea-AI Summary

BD announced the global availability of its new molecular PCR assay for monkeypox virus, developed in collaboration with CerTest Biotec. This assay is intended for research use only and is now accessible worldwide, including in the U.S. BD is also preparing to submit a clinical test for emergency use authorization. The BD MAX™ System, which supports this assay, features rapid nucleic acid extraction and PCR capabilities. The new test aims to enhance monkeypox research amidst the ongoing public health emergency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
Rhea-AI Summary

LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
management
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has launched the BD EffivaxTM Glass Prefillable Syringe, designed in collaboration with leading pharmaceutical firms. This next-generation syringe aims to enhance vaccine manufacturing efficiency by addressing critical aspects such as processability, contamination, and integrity. With about 70% of top biopharmaceutical companies relying on BD, this innovation is set to meet increasing global demand for prefillable syringes, particularly due to the growth in vaccine pipelines. Additionally, BD continues to invest $1.2 billion in enhancing its manufacturing capacity for these products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has announced the promotion of Mike Garrison to EVP and President of the Medical segment, and Rick Byrd to EVP and President of the Interventional segment, effective Sept. 6. Both leaders bring extensive experience from their previous roles within the company. Garrison will focus on advancing innovation and portfolio strategy, while Byrd will continue to drive growth and operational excellence in his segment. The decision follows the upcoming departure of Simon Campion, who is leaving for another executive role.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) will present at the Wells Fargo 2022 Healthcare Conference on September 7, 2022, at 12:30 PM Eastern Time. Interested parties can access the live webcast via the BD investor relations website, with a replay available afterwards. BD is a leading global medical technology company focused on enhancing healthcare quality through innovation. With a strong commitment to improving medical discovery and diagnostics, BD operates globally, aiming to tackle pressing health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences

FAQ

What is the current stock price of Becton, Dickinson and Co. (BDX)?

The current stock price of Becton, Dickinson and Co. (BDX) is $226.44 as of December 23, 2024.

What is the market cap of Becton, Dickinson and Co. (BDX)?

The market cap of Becton, Dickinson and Co. (BDX) is approximately 65.3B.

What does Becton, Dickinson and Company (BD) specialize in?

BD specializes in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products.

What are BD's main business segments?

BD’s main business segments include BD Medical, BD Life Sciences, and BD Interventional.

What recent projects has BD undertaken?

BD has collaborated on recycling used blood collection tubes in Denmark and launched new cell sorters for enhanced research in cell biology, cancer, and immunology.

How much of BD's revenue comes from international markets?

International revenue accounts for 43% of BD's total business.

What significant acquisition has BD announced recently?

BD announced the acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion.

How many employees does BD have?

BD has over 70,000 employees globally.

Where can I find more information about BD's financial performance?

Information about BD's financial performance can be found on their investor relations website at www.bd.com/investors.

What is the significance of the BD FACSDiscover™ S8 Cell Sorters?

The BD FACSDiscover™ S8 Cell Sorters enable real-time imaging and spectral flow cytometry, allowing researchers to gain new insights in various scientific fields.

Which regulatory body recently issued a safety communication regarding syringes?

The U.S. Food and Drug Administration (FDA) issued the safety communication.

What is BD's approach to sustainability?

BD is committed to sustainable innovation, including collaborations to recycle medical plastics and initiatives to minimize its environmental footprint.

Becton, Dickinson and Co.

NYSE:BDX

BDX Rankings

BDX Stock Data

65.29B
288.35M
0.28%
91.75%
0.73%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
FRANKLIN LAKES